Skip to main content
. 2019 Sep 3;42(11):1106–1112. doi: 10.1002/clc.23261

Table 2.

Events by EF categories

Outcome N (%) events Event rates Crude HR (95%CI) p value Adj. HR (95%CI)a p value
Primary outcome
EF < 40% 1344 (22.9) 19.2 (18.2–20.2) Ref. <.001 Ref. <.001
EF = 40% 100 (13.3) 10.3 (8.5–12.5) 0.55 (0.44‐0.67) 0.65 (0.53‐0.81)
CV death
EF < 40% 833 (14.2) 10.9 (10.2‐11.7) Ref. <.001 Ref. <.001
EF = 40% 52 (6.9) 5.0 (3.8‐6.6) 0.47 (0.35‐0.62) 0.58 (0.43‐0.77)
All‐cause death
EF < 40% 959 (16.4) 12.6 (11.8–13.4) Ref. <.001 Ref. .001
EF = 40% 68 (9.0) 6.6 (5.2–8.4) 0.53 (0.41‐0.68) 0.65 (0.50–0.83)
HF hospitalization
EF < 40% 787 (13.4) 11.2 (10.5‐12.0) Ref. <.001 Ref. .008
EF = 40% 64 (8.5) 6.6 (5.2–8.4) 0.60 (0.46‐0.77) 0.70 (0.53‐0.91)

Note: The primary outcome is a composite of cardiovascular death or cardiovascular hospitalization. Median follow‐up time to death or censor = 1.3 (1.0‐1.7) years. Event rates per 100 person‐years.

Abbreviations: CV, cardiovascular; EF, left ventricular ejection fraction; HF, heart failure.

a

Model adjusted on age, sex, body mass index, heart rate, estimated glomerular filtration rate, sodium, potassium, previous myocardial infarction, peripheral vascular disease, previous heart failure hospitalization, atrial fibrillation, diabetes, hypertension, chronic obstructive pulmonary disease, angiotensin‐converting‐enzyme‐inhibitors/angiotensin‐receptor blockers, beta‐blockers, Q‐wave myocardial infarction, Killip class, reperfusion therapy, and study drug (eplerenone or placebo).